StocksMedium•4 November 2026•
1 min read
Flyte Aviation Signs LOI to Sell Catheter Precision Assets in Pivot to Private Aviation
Key Facts
1Flyte Aviation executed a non-binding Letter of Intent to sell its Catheter Precision subsidiary assets, including VIVO and LockeT product lines.
2The divestiture aims to complete the company's transition to a pure-play tech-enabled private aviation firm and reduce operating expenses.
Flyte Aviation executed a non-binding Letter of Intent to sell the assets of its subsidiary Catheter Precision, including the VIVO and LockeT product lines. According to a statement on PR Newswire, the divestiture is designed to complete the company's transition into a pure-play tech-enabled private aviation firm and reduce operating expenses.
The sale aligns with Flyte Aviation's strategy to streamline operations and focus exclusively on its aviation business, with plans to use the proceeds to fund jet fleet expansion and other growth initiatives. Sentiment for VTAK remains positive as the company pivots away from its legacy cardiology and life sciences assets.